Companies · Pharmaceuticals

Oxygen Therapy, Inc.

NEWTON · Pharmaceuticals

Diligence memoA one-page analyst read on Oxygen Therapy, Inc. — recommendation, valuation, rhythm, risks.
$540K
Total raised · real
2
Rounds
1.3×
Latest step-up
Top 88%
Sector rank · raised
Pre-Seed
Latest stage · inferred · Fri Aug 19 2016 00:00:00 GMT+0000 (Coordinated Universal Time)

Oxygen Therapy, Inc. looks fair against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the pharma sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Fair
  • Modeled value is 0.75× the median modeled value of Pre-Seed Pharmaceuticals companies in 2016–2018 (56 peers) — value vs value, same stage and era.
  • Within the normal band (75% of peer median) for its niche.
Dormant
  • Last raise 9.9 yr ago; this sector typically re-raises about every 13 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Pharmaceuticals

Oxygen Therapy, Inc. is one of 1610 Pharmaceuticals companies tracked from NEWTON. By capital raised it ranks in the long tail (ahead of 13% of sector peers), and in the long tail by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
No revenue
Issuer revenue
Rule 506(b)
Reg D exemption
12
Investors (latest)
2016
Year incorporated
2016-08-19
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$5.0M$10M$15M$20MPre-Seed · 2016-06-06 Raised $240K (real) Modeled valuation $11M (est)$240K$11MPre-Seed2016Pre-Seed · 2016-08-19 Raised $300K (real) Modeled valuation $14M (est)$300K$14MPre-Seed2016+$300KCumulative $540K

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Pre-Seed$240K · 2016
Pre-Seed extension$300K · 2016

Stages are modeled from round size (public records carry no series label). Ladder is contiguous — every modeled rung has a record.

Modeled valuation trajectory
$14.2M
Base estimate est.
$168K
Conservative case
$160.9M
Upside case
$1.7M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Pre-Seeda round under $1.0M). Valuation is modeled from stage benchmarks scaled by the pharma sector profile. Directional, not a quoted figure.

Pre-Seed · modeled $11.4M · 2016-06-062016Pre-Seed · modeled $14.2M · 2016-08-192016
Model inputs · modeled:benchmark-stage-stepup-v1
18%
Dilution assumption
Implied ownership sold in the financing.
25%
Survival probability
10% low · 46% high
1.80×/yr
Annual markup
2.44×/yr upside case
6.0 yr
Elapsed time used
9.9 yr actual, capped for stale marks
pharma
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
2 mo
Avg between rounds
Capital velocity
10.1 yr
On record since
2016
First round
2
Rounds on file
How it compares to the market

Benchmarked against 1610 companies in Pharmaceuticals. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 0.1× of median
This company$540K
Sector median$8.1M
Latest round — vs other Pre-Seed rounds in sector (real $, this stage) 0.7× of median
This company$300K
Sector median$421K
Modeled value — vs sector median (estimate, all stages) 0.2× of median
This company$14.2M
Sector median$76.1M

Raised more than 13% of sector peers (real $). Modeled value above 23% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Pre-Seed) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #39 of 56.

This companyCohort peer
$10.0M$100.0M$100K$1.0M$10.0MCapital raised (log)Novellus LLC · Pre-Seed Raised $3.0M · modeled $47.3M (est)Blake Insomnia Therapeutics, Inc. · Pre-Seed Raised $1.0M · modeled $47.3M (est)Essentia Pharma Socal, Llc · Pre-Seed Raised $1.0M · modeled $47.3M (est)Essentia Pharma Florida, Llc · Pre-Seed Raised $1.0M · modeled $47.3M (est)Eleusis Benefit Corporation, PBC · Pre-Seed Raised $1.7M · modeled $46.2M (est)Blc Usa Lp · Pre-Seed Raised $813K · modeled $38.5M (est)T.A.Z. Corp · Pre-Seed Raised $813K · modeled $38.5M (est)ReveraGen BioPharma, Inc. · Pre-Seed Raised $800K · modeled $37.8M (est)Cyto-Sen Therapeutics, Inc. · Pre-Seed Raised $800K · modeled $37.8M (est)WinSanTor · Pre-Seed Raised $783K · modeled $37.0M (est)Pelagius Inc. · Pre-Seed Raised $750K · modeled $35.5M (est)Apothecary Health Solutions, LLC · Pre-Seed Raised $725K · modeled $34.3M (est)Oxygen Therapy, Inc. (this company) Raised $540K · modeled $14.2M (est)Oxygen Therapy, Inc.
CompanyStageRaised · realValue · estvs peer med.
Novellus LLCPre-Seed$3.0M$47.3M2.50×
Blake Insomnia Therapeutics, Inc.Pre-Seed$1.0M$47.3M2.50×
Essentia Pharma Socal, LlcPre-Seed$1.0M$47.3M2.50×
Essentia Pharma Florida, LlcPre-Seed$1.0M$47.3M2.50×
Eleusis Benefit Corporation, PBCPre-Seed$1.7M$46.2M2.44×
Blc Usa LpPre-Seed$813K$38.5M2.03×
T.A.Z. CorpPre-Seed$813K$38.5M2.03×
ReveraGen BioPharma, Inc.Pre-Seed$800K$37.8M2.00×
Cyto-Sen Therapeutics, Inc.Pre-Seed$800K$37.8M2.00×
WinSanTorPre-Seed$783K$37.0M1.96×
Pelagius Inc.Pre-Seed$750K$35.5M1.87×
Apothecary Health Solutions, LLCPre-Seed$725K$34.3M1.81×
Oxygen Therapy, Inc. this companyPre-Seed$540K$14.2M0.75×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Pre-Seed$240K2016-06-06$1.3M$11.4M90%
Pre-Seed$300K2016-08-19$1.7M$14.2M85%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Pre-Seed$240K2016-06-06
    • First recorded raise — entered as Pre-Seed.
    • 10 investors on this round.
  2. Pre-Seed$300K2016-08-19
    • Came back fast: 2 mo vs the ~13 mo sector norm.
    • Round roughly the size of the prior one.
    • 12 investors on this round.
Intelligence
2016 ~Q4
Modeled next raise · ~2mo cadence
$375K
Modeled next size est.range $300K$600K
1.3×
Last step-up
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
David Platt3 other2016-06
Dale H. Conaway2 other2016-06
Henry J. Esber2 other2016-06
Ola Soderquist2 other2016-06
Alan J. Hoberman2016-06
Yuval Kwintner2016-06
Registry & provenance

Oxygen Therapy, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1685616
SEC CIK
2016
Incorporated
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Bioxytran, IncBiotechnologySeed$6.0M$1.5Mnetwork4 shared operators
Alphageneron Pharmaceuticals, Inc.PharmaceuticalsPre-Seed$250K$2.1Mnetwork1 shared operator · same sector · same stage
Pradama IncPharmaceuticalsPre-Seed$550K$14.2Msame sector · same stage
Lattice Biotech, LLCPharmaceuticalsPre-Seed$512K$24.2Msame sector · same stage
Gelesis Holdings, Inc.PharmaceuticalsPre-Seed$576K$7.9Msame sector · same stage
Sincerus Pharmaceuticals IncPharmaceuticalsPre-Seed$506K$23.9Msame sector · same stage
Pharmagen, Inc.PharmaceuticalsPre-Seed$506K$5.0Msame sector · same stage
Lavior IncPharmaceuticalsPre-Seed$580K$13.3Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
OX2 Therapeutics, Inc.BiotechnologyPre-Seed$32.9M81%
Owp Pharmaceuticals, Inc.PharmaceuticalsSeed$6.6M80%
Fog Pharmaceuticals, Inc.PharmaceuticalsSeries D+$3.1B80%
Eleos Pharmaceuticals, Inc.PharmaceuticalsPre-Seed$12.1M80%
Khloris Biosciences, Inc.PharmaceuticalsSeries A$154.9M80%
Cambridge Therapeutic Technologies, LLCPharmaceuticalsSeries A$185.8M79%
FibroBiologics, Inc.PharmaceuticalsSeed$3.8M79%
Lung Therapeutics, Inc.PharmaceuticalsSeries B$174.7M79%
Frequently asked
How much funding has Oxygen Therapy, Inc. raised?
Oxygen Therapy, Inc. has raised approximately $540K in disclosed capital across 2 recorded financing rounds, aggregated from public filings.
What is Oxygen Therapy, Inc.'s estimated valuation?
Provath's modeled valuation for Oxygen Therapy, Inc. is approximately $14.2M (modeled range $168K–$160.9M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Oxygen Therapy, Inc. at?
Oxygen Therapy, Inc.'s latest modeled financing stage is Pre-Seed. Its most recent recorded round closed around Fri Aug 19.
What does Oxygen Therapy, Inc. do and where is it based?
Oxygen Therapy, Inc. operates in the Pharmaceuticals sector, based in NEWTON.
Explore related

See where Oxygen Therapy, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Oxygen Therapy, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.